• Karyopharm Therapeutics filed for Chapter 11 protection in the Southern District of Texas to pursue a merger with Ayrmid.
• Ayrmid will serve as lead bidder in a court-supervised sale process allowing competing offers for the company's assets.
• The merger is expected to close in the first quarter of 2027, subject to conditions in the Chapter 11 plan.
• Existing secured lenders committed up to $55 million in debtor-in-possession financing, subject to court approval.
• Operations are expected to continue uninterrupted during restructuring, including advancement of multiple myeloma and myelofibrosis programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611020710PR_NEWS_USPR_____NY86323) on November 02, 2026, and is solely responsible for the information contained therein.